Anne C. Chiang

10.0k total citations · 4 hit papers
88 papers, 3.1k citations indexed

About

Anne C. Chiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anne C. Chiang has authored 88 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Anne C. Chiang's work include Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (26 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Anne C. Chiang is often cited by papers focused on Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (26 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Anne C. Chiang collaborates with scholars based in United States, Spain and Canada. Anne C. Chiang's co-authors include Joan Massagué, Paula D. Bos, Don X. Nguyen, Roger R. Gomis, Gaorav P. Gupta, Katia Manova‐Todorova, Cristina Nadal, Maureen F. Zakowski, Mark G. Kris and Gregory J. Riely and has published in prestigious journals such as Nature, New England Journal of Medicine and JAMA.

In The Last Decade

Anne C. Chiang

80 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Basis of Metastasis

2008 783 citations Anne C. Chiang, Joan Massagué New England Journal of Medicine profile →
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis

2007 548 citations Gaorav P. Gupta, Don X. Nguyen et al. Nature profile →
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03

2025 18 citations Afshin Dowlati, Anne C. Chiang et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne C. Chiang United States	19	1.9k	1.2k	1.1k	682	227	88	3.1k
Sara Pilotto Italy	29	1.8k 1.0×	1.1k 0.9×	813 0.7×	485 0.7×	324 1.4×	187	2.9k
Odd Terje Brustugun Norway	30	1.4k 0.8×	1.3k 1.0×	1.1k 1.0×	680 1.0×	250 1.1×	136	2.9k
Young Joo Min South Korea	28	1.4k 0.8×	1.3k 1.1×	1.0k 0.9×	560 0.8×	143 0.6×	106	2.7k
Paolo Maione Italy	31	2.2k 1.2×	2.0k 1.6×	1.1k 1.0×	452 0.7×	233 1.0×	138	3.6k
Alastair Greystoke United Kingdom	28	2.3k 1.3×	1.3k 1.1×	1.3k 1.1×	1.4k 2.0×	274 1.2×	144	3.8k
Yuan Yuan United States	30	1.7k 0.9×	735 0.6×	1.5k 1.4×	1.2k 1.7×	205 0.9×	168	3.6k
José Alejandro Pérez Fidalgo Spain	27	1.4k 0.8×	569 0.5×	1.3k 1.1×	853 1.3×	148 0.7×	136	2.9k
Toshinari Yamashita Japan	24	1.9k 1.0×	1.6k 1.3×	1.3k 1.2×	1.1k 1.6×	212 0.9×	135	3.7k
Janessa Laskin Canada	30	2.2k 1.2×	2.1k 1.7×	1.0k 0.9×	774 1.1×	288 1.3×	187	3.8k
Erica L. Mayer United States	31	2.6k 1.4×	997 0.8×	1.4k 1.2×	1.2k 1.8×	152 0.7×	144	4.7k

Countries citing papers authored by Anne C. Chiang

Since Specialization

Citations

This map shows the geographic impact of Anne C. Chiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne C. Chiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne C. Chiang more than expected).

Fields of papers citing papers by Anne C. Chiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne C. Chiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne C. Chiang. The network helps show where Anne C. Chiang may publish in the future.

Co-authorship network of co-authors of Anne C. Chiang

This figure shows the co-authorship network connecting the top 25 collaborators of Anne C. Chiang. A scholar is included among the top collaborators of Anne C. Chiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne C. Chiang. Anne C. Chiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bourla, Ariel B., Katja Schulze, Sophia L. Maund, et al.. (2025). Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications. 44. 101446–101446. 1 indexed citations

Dowlati, Afshin, Anne C. Chiang, Andrés Cervantes, et al.. (2025). Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. Journal of Thoracic Oncology. 20(6). 799–808. 18 indexed citations breakdown →

Shields, Misty Dawn, Anne C. Chiang, & Lauren A. Byers. (2025). Top advances of the year: Small cell lung cancer. Cancer. 131(6). e35770–e35770.

Chiang, Anne C., Noemı́ Reguart, Philipp J. Jost, et al.. (2024). 155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. Immuno-Oncology Technology. 24. 100784–100784. 1 indexed citations

Chiang, Anne C., et al.. (2024). Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives. American Society of Clinical Oncology Educational Book. 44(3). e432520–e432520. 2 indexed citations

Park, Henry S., et al.. (2024). Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.. Journal of Clinical Oncology. 42(16_suppl). e20136–e20136. 1 indexed citations

Chandana, Sreenivasa R, Noura J. Choudhury, Afshin Dowlati, et al.. (2024). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3001–3001. 10 indexed citations

Schalper, Kurt A., et al.. (2024). Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resistance. 7. 55–55.

Chiang, Anne C., Scott Gettinger, Sarah B. Goldberg, et al.. (2023). Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 8597–8597. 1 indexed citations

10.

Gettinger, Scott, Frederick H. Wilson, Sarah B. Goldberg, et al.. (2023). Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.. Journal of Clinical Oncology. 41(16_suppl). 9121–9121. 1 indexed citations

11.

Stover, Angela M., Benjamin Y. Urick, Allison M. Deal, et al.. (2019). ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES. Value in Health. 22. S413–S413. 1 indexed citations

12.

Uhlig, Johannes, Johannes Ludwig, Sarah B. Goldberg, et al.. (2018). Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non–Small Cell Lung Cancer: A National Cancer Database Study. Radiology. 289(3). 862–870. 66 indexed citations

13.

Chiang, Anne C., Melissa Pavilack, François Laliberté, et al.. (2018). MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal of Thoracic Oncology. 13(10). S410–S411. 14 indexed citations

14.

Decker, Roy H., Sarah B. Goldberg, Sameer K. Nath, et al.. (2017). P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC. Journal of Thoracic Oncology. 12(1). S1303–S1304. 3 indexed citations

15.

Daniel, Davey B., Charles M. Rudin, L. Hart, et al.. (2017). Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals of Oncology. 28. v540–v540. 15 indexed citations

16.

Suozzi, Kathleen C., Maximilian Stahl, Christine J. Ko, et al.. (2016). Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports. 2(3). 264–268. 80 indexed citations

17.

Bleich, Sara N., Cheryl Sherrod, Anne C. Chiang, et al.. (2015). Systematic Review of Programs Treating High-Need and High-Cost People With Multiple Chronic Diseases or Disabilities in the United States, 2008–2014. Preventing Chronic Disease. 12. E197–E197. 59 indexed citations

18.

Chiang, Anne C. & Joan Massagué. (2008). Molecular Basis of Metastasis. New England Journal of Medicine. 359(26). 2814–2823. 783 indexed citations breakdown →

19.

Gupta, Gaorav P., Don X. Nguyen, Anne C. Chiang, et al.. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 446(7137). 765–770. 548 indexed citations breakdown →

20.

Balak, Marissa N., Yixuan Gong, Gregory J. Riely, et al.. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research. 12(21). 6494–6501. 664 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact